Clancy J. Paul's Insider Trades & SAST Disclosures
Clancy J. Paul's most recent trade in Incyte Corp. was a trade of 358 Common Stock done at an average price of $60.6 . Disclosure was reported to the exchange on March 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Clancy J. Paul.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 60.55 per share. | 31 Mar 2025 | 358 | 20,071 (0%) | 0% | 60.6 | 21,677 | Common Stock |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 69.07 per share. | 31 Dec 2024 | 331 | 19,713 (0%) | 0% | 69.1 | 22,862 | Common Stock |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 66.10 per share. | 30 Sep 2024 | 368 | 19,382 (0%) | 0% | 66.1 | 24,325 | Common Stock |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 60.62 per share. | 28 Jun 2024 | 399 | 19,014 (0%) | 0% | 60.6 | 24,187 | Common Stock |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Exact Sciences Corp. | Paul Clancy J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,939 | 20,640 (0%) | 0% | 0 | Common Stock | |
| Exact Sciences Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,444 | 20,145 (0%) | 0% | 0 | Common Stock | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 12,517 | 12,517 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,830 | 18,615 (0%) | 0% | 0 | Common Stock | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 56.97 per share. | 28 Mar 2024 | 403 | 15,785 (0%) | 0% | 57.0 | 22,959 | Common Stock |
| Incyte Corp. | Clancy J. Paul | Director | Grant, award, or other acquisition of securities at price $ 62.79 per share. | 29 Dec 2023 | 412 | 15,382 (0%) | 0% | 62.8 | 25,869 | Common Stock |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 62.25 per share. | 30 Jun 2023 | 380 | 14,591 (0%) | 0% | 62.3 | 23,655 | Common Stock |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 11,294 | 11,294 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 2,505 | 14,211 (0%) | 0% | 0 | Common Stock | |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Exact Sciences Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 3,599 | 14,701 (0%) | 0% | 0 | Common Stock | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 72.27 per share. | 31 Mar 2023 | 318 | 11,706 (0%) | 0% | 72.3 | 22,982 | Common Stock |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 80.32 per share. | 30 Dec 2022 | 294 | 11,388 (0%) | 0% | 80.3 | 23,614 | Common Stock |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 66.64 per share. | 30 Sep 2022 | 339 | 11,094 (0%) | 0% | 66.6 | 22,591 | Common Stock |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 75.97 per share. | 30 Jun 2022 | 321 | 10,755 (0%) | 0% | 76.0 | 24,386 | Common Stock |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 9,124 | 9,124 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,144 | 10,434 (0%) | 0% | 0 | Common Stock | |
| Exact Sciences Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 5,606 | 11,102 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 6,549 (0%) | 0% | 0 | Common stock | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 79.42 per share. | 31 Mar 2022 | 326 | 8,290 (0%) | 0% | 79.4 | 25,891 | Common Stock |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2021 | 65,528 | 65,528 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2021 | 44,033 | 44,033 | - | - | Stock Option (right to buy) | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 68.78 per share. | 30 Sep 2021 | 321 | 7,621 (0%) | 0% | 68.8 | 22,078 | Common Stock |
| Exact Sciences Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,567 | 5,496 (0%) | 0% | 0 | Common Stock | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 84.13 per share. | 30 Jun 2021 | 283 | 7,300 (0%) | 0% | 84.1 | 23,809 | Common Stock |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 4,964 (0%) | 0% | 0 | Common stock | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 8,010 | 8,010 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 1,923 | 7,017 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 8,888 | 8,888 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 1,585 | 1,585 | - | - | Restricted stock unit | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 81.27 per share. | 31 Mar 2021 | 298 | 5,094 (0%) | 0% | 81.3 | 24,218 | Common Stock |
| Exact Sciences Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2021 | 2,929 | 2,929 (0%) | 0% | 0 | Common Stock | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 89.74 per share. | 30 Sep 2020 | 260 | 4,515 (0%) | 0% | 89.7 | 23,332 | Common Stock |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 103.97 per share. | 30 Jun 2020 | 229 | 4,255 (0%) | 0% | 104.0 | 23,809 | Common Stock |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 8,096 | 8,096 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2020 | 1,878 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2020 | 1,878 | 3,278 (0%) | 0% | - | Common stock | |
| Agios Pharmaceuticals Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 1,686 | 1,686 | - | - | Restricted stock units | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 10,514 | 10,514 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 1,282 | 4,026 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges